T1	Participants 351 488	10 geographically-dispersed screening centers participating in the ongoing Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
T2	Participants 509 541	64,554 participants (aged 55-74)
T3	Participants 1650 1678	patients with inadequate FSG
